Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06764771 · ClinicalTrials.gov registry record · Phase 1
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
A Phase 1 study of Advanced Malignant Tumors, sponsored by Bristol-Myers Squibb.
- Active
- Registry status
- Phase 1
- Development phase
- 437
- Enrollment target
- 7
- Study locations
NCT06764771: Active Phase 1 study of Advanced Malignant Tumors, sponsored by Bristol-Myers Squibb.
NCT06764771 is a Phase 1 study of Advanced Malignant Tumors that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 437 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (628% higher). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06764771, a Phase 1 study of Advanced Malignant Tumors, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 437 participants
- Enrollment target
- 7
- Study locations
Study Summary
This purpose of this study is to determine if experimental treatment with BMS-986488, alone, or in combinations is safe, tolerable, and has anti-cancer activity in patients with advanced malignant tumors.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Cetuximab
- DRUG Adagrasib
- DRUG BMS-986488
Study Locations (7)
Quebec
- Local Institution - 0015 - Montreal
- Local Institution - 0016 - Québec
New Jersey
- Local Institution - 0021 - Hackensack
Pennsylvania
- Local Institution - 0020 - Allentown
Tennessee
- Local Institution - 0024 - Germantown
Queensland
- Local Institution - 0031 - Brisbane
British Columbia
- Local Institution - 0032 - Vancouver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 437 participants |
| Start Date | 2025-03-25 |
| Est. Completion | 2027-10-15 |
| Phase | Phase 1 |
What the registry record for NCT06764771 still lists
NCT06764771 is an interventional study that assigns participants to a tested intervention. The registered 437 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (628% higher).
The record links to 1 condition, with Advanced Malignant Tumors appearing as the primary indexed condition, and to 4 interventions - of which Nivolumab is the first listed.
NCT06764771 lists 7 locations in 6 states (Quebec, New Jersey, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT06764771 about?
NCT06764771 is a clinical study titled "A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors". This purpose of this study is to determine if experimental treatment with BMS-986488, alone, or in combinations is safe, tolerable, and has anti-cancer activity in patients with advanced malignant tumors.
What is the current status of trial NCT06764771?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 437 participants. The study started on 2025-03-25. Estimated completion is 2027-10-15.
What conditions does trial NCT06764771 study?
This clinical trial studies the following conditions: Advanced Malignant Tumors.
What interventions are being tested in trial NCT06764771?
The interventions under investigation include: Nivolumab (DRUG), Cetuximab (DRUG), Adagrasib (DRUG), BMS-986488 (DRUG).
Who is sponsoring clinical trial NCT06764771?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06764771 being conducted?
This trial has 7 study locations across New Jersey, Pennsylvania, Tennessee, Queensland, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06764771's enrollment target sits among peer trials
437 62nd of 2000 higher than 1,939 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05711446 · 438 participants · NA
Double Voiding and Post-transplant UTI
- NCT02622542 · 436 participants · NA
ACute Uncomplicated Type b Aortic Dissection: Endovascular Repair vs. Best Medical Therapy
- NCT05918211 · 436 participants · Phase 3
Fontan Udenafil Exercise Longitudinal Assessment Trial - 2
- NCT06966479 · 436 participants · Phase 2
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI